Regeneron Pharmaceuticals, Inc. Stock price

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
959.9 USD -0.47% Intraday chart for Regeneron Pharmaceuticals, Inc. -0.47% +9.29%
Sales 2024 * 13.89B Sales 2025 * 14.87B Capitalization 103B
Net income 2024 * 4.16B Net income 2025 * 4.56B EV / Sales 2024 * 6.79 x
Net cash position 2024 * 8.91B Net cash position 2025 * 12.78B EV / Sales 2025 * 6.08 x
P/E ratio 2024 *
26.1 x
P/E ratio 2025 *
23.7 x
Employees 13,450
Yield 2024 *
-
Yield 2025 *
-
Free-Float 77.18%
More Fundamentals * Assessed data
Dynamic Chart
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
US appeals court revives Regeneron's antitrust lawsuit against Novartis RE
Regeneron Pharmaceuticals Insider Sold Shares Worth $5,531,290, According to a Recent SEC Filing MT
2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene Therapy DJ
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-13-2024 10:40 AM
Morgan Stanley Raises Price Target on Regeneron Pharmaceuticals to $1,115 From $1,104, Maintains Overweight Rating MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 11:15 AM
Regeneron Says FDA Extends Approval of Praluent to Treat Children, Teens With Genetic High-Cholesterol MT
Regeneron Pharmaceuticals, Inc.'s Praluent® Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol CI
Regeneron Says Results From Phase 3 Trials of Eylea HD Met Their Primary Endpoints; Were Published by The Lancet MT
Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg CI
Boehringer to cut out-of-pocket costs for inhalers to $35 RE
Transcript : Regeneron Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-06-2024 11:10 AM
Regeneron Pharmaceuticals Insider Sold Shares Worth $346,365, According to a Recent SEC Filing MT
Biocon Arm to Launch Colorectal Cancer Biosimilar in Canada MT
More news
1 day-0.47%
1 week-0.92%
Current month-0.64%
1 month+1.25%
3 months+11.73%
6 months+16.58%
Current year+9.29%
More quotes
1 week
950.97
Extreme 950.97
979.82
1 month
943.73
Extreme 943.73
998.33
Current year
871.39
Extreme 871.39
998.33
1 year
684.81
Extreme 684.805
998.33
3 years
451.60
Extreme 451.6
998.33
5 years
271.37
Extreme 271.37
998.33
10 years
269.50
Extreme 269.5
998.33
More quotes
Managers TitleAgeSince
Founder 64 88-01-07
Chief Executive Officer 71 88-01-07
Director of Finance/CFO 54 02-12-31
Members of the board TitleAgeSince
Director/Board Member 71 10-11-11
Chief Executive Officer 71 88-01-07
Director/Board Member 82 91-05-31
More insiders
Date Price Change Volume
24-03-18 959.9 -0.47% 360,302
24-03-15 964.5 +0.57% 1,090,502
24-03-14 959 -0.67% 507,315
24-03-13 965.5 -0.53% 386,222
24-03-12 970.6 +0.64% 359,030

Delayed Quote Nasdaq, March 18, 2024 at 04:30 pm EDT

More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
959.9 USD
Average target price
1,017 USD
Spread / Average Target
+5.97%
Consensus
  1. Stock
  2. Equities
  3. Stock Regeneron Pharmaceuticals, Inc. - Nasdaq